DLRS
Other DLRS Links
Licensing and Regulatory Servcies
State House Station #11
41 Anthony Avenue
Augusta Maine 04333
Telephone: 1-800-791-4080
(207)287-9300
TDD Number: 1-800-606-0215

Social
Services Help
|
Community Services Programs
Children Mental Health Rights; Rules of General Applicability -
Protection During Experimentation Research
A. Recipients have the right to refuse to participate
in experimentation and research without loss of
services.
B. All participation in experimentation and research
shall be voluntary with full written informed consent,
except as provided in these rules.
C. A recipient's refusal to participate in a research
project or an experimental activity shall not be
cause for denying the provision of indicated services
to that recipient.
D. Definitions
- Experimentation and research
- Experimentation and research means the
use of any medical, behavioral, or environmental
intervention involving practices not commonly
accepted by the discipline involved, or the
systematic accumulation and codification of
data designed to develop or contribute to
general knowledge.
- Experimental drug use means:
- the use of any Food and Drug Administration
non-approved drug.
- Informed consent means the agreement obtained
from a subject, or from his or her authorized representative,
to participate in an activity. Informed consent
requires that subjects understand the purpose, benefits
and risks of research in which they are asked to
participate and are given the opportunity to consent
to, reject, or withdraw from participation without
penalty.
- Minimal risk means that the risk of harm anticipated
in the proposed research or experimentation is not
greater, considering probability and magnitude,
than that ordinarily encountered in daily life or
during the performance of routine physical or psychological
examinations or tasks.
- Board means the Research and Experimentation
Review Board.
E. Research and Experimentation Review Board Membership
- A. Research and Experimentation Review Board,
selected by the administrative head of the particular
facility or agency, shall have at least five members
with varying backgrounds, in order to promote complete
and adequate review of research and experimental
activities proposed for consideration.
- The Board shall be sufficiently qualified,
through the experience and expertise of its members
and the diversity of the members' backgrounds, to
promote respect for its advice and counsel in safeguarding
the rights and welfare of human subjects.
- In addition to possessing the professional
competence necessary to review such activities,
the Board shall be able to ascertain the acceptability
of proposed research or experimentation in terms
of institutional commitments, regulations, applicable
law, and standards of professional conduct and practice.
- The Board shall consist of interdisciplinary
members of both sexes including at least one member
whose primary concerns are in non-scientific areas,
such as law, ethics or theology, and at least one
member who is not otherwise affiliated with the
institution or agency proposing the research or
experimentation.
- No Board member may participate in the Board's
initial or continuing review of any project in which
the member has a conflicting interest, except to
provide information requested by the Board.
- At the Board's discretion, individuals with
competence in special areas may be invited to assist
in the review of complex issues which require expertise
beyond or in addition to that available on the Board.
These individuals may not vote.
F. General Procedures
- All experimentation and research shall commence
only after review and approval by the Research and
Experimentation Review Board.
- The Research and Experimentation Review Board
shall have the authority to approve, require modifications
in, or disapprove, any proposed research or experimentation
activities.
- The Rights Protection or Advocacy Agency of
the Maine mental health system shall be informed
of any proposed experimentation or research involving
more than minimal risk.
- The Board shall maintain adequate documentation
of its activities.
- The Board shall provide written notification
of its approval or disapproval of the proposed research
or experimentation activity or of any modifications
required to secure research and experimentation
review board approval of any activity in question.
- If the Board decides to disapprove a research
or experimentation activity, it shall include, in
its written notification, a statement of the reasons
for its decision and give the investigator an opportunity
to respond in person or in writing.
- Investigators and others directly involved
in the research or experimentation shall, both in
obtaining the consent and in conducting research,
adhere to the ethical and research standards of
their respective professions concerning the conduct
of research or experimentation and to the regulations
for research involving human subjects required by
the U.S. Department of Health and Human Services
in effect at the time of the adoption of these rules.
- Researchers must report substantial changes
or unanticipated problems immediately to the Chairperson
of the Board.
- The Board shall conduct continuing review
of research covered by these regulations at intervals
appropriate to the degree of risk, but not less
than once a year, and shah have authority, to observe
or have a third party observe the consent process
and research.
- The Board shall have the authority to suspend
or terminate approval of research that is not being
conducted in accordance with the Board's requirements,
these rules, or that has been associated with unexpected
harm to subjects. Any suspension or termination
of approval shall include a statement of the reasons
for the Board's action and shall be reported promptly
to the investigator, appropriate institutional officials,
and the secretary of the Department of Health and
Human Services as required by federal regulations.
- Upon completion of the research and/or experimentation
procedures the principal investigator shall attempt
to remove any confusion, stress, physical discomfort,
or other harmful consequences that may have been
inadvertently produced as a result of the research
or experimentation procedures.
G. Criteria for Board Approval of Research and
Experimentation. In order to approve research covered
by these regulations the Board shall determine that
all of the following requirements are satisfied:
- Risks to subjects are minimized by using procedures
which are consistent with sound research or experimentation
design and which do not unnecessarily expose subjects
to risk and, wherever appropriate, by using procedures
already, being performed on the subject for diagnostic
or treatment purposes.
- Risks to subjects are reasonable in relationship
to anticipated benefits to subjects. In evaluating
risks and benefits, the Board shall consider only
those risks and benefits that may result from the
research and experimentation, as distinguished from
the risks and benefits of therapy these subjects
would receive in not participating in the research,
or possible long-range benefits of applying knowledge
gained in the research.
- Selection of subjects is equitable, taking
into account the purposes of the research and the
setting in which the research will be conducted.
- Informed consent will be sought and appropriately
documented in accordance with these rules.
- The research or experimentation plan makes
adequate provisions for monitoring the data collected
or the activities allowed to ensure the safety of
the subjects.
- There are adequate provisions to protect the
privacy of subjects and to maintain the confidentiality
of data.
- Where some or all of the subjects are likely
to be vulnerable to coercion or undue influence,
appropriate additional safeguards have been included
in the project to protect the rights and welfare
of these subjects.
H. Special Procedures; Exceptions to Informed
Consent
- Research Involving the Need for Non-disclosure
- If the research or experimentation methodology
requires that the purpose, nature, expected
outcome and/or implications of the research
not be disclosed to the participants before
it begins, the researcher shall clearly and
vigorously justify to the Research and Experimentation
Review Board the need for non-disclosure.
- The Board may approve research or experimentation
procedures which do not include, or which alter,
some or all of the elements of informed consent
set forth in these rules, or waive the requirements
to obtain informed consent provided the Board
finds and documents that:
- the research involves no more than
minimal risks to the subjects;
- the waiver or alteration will not
adversely affect the rights and welfare
of the subjects;
- the research or experimentation
could not practicably be carried out without
the waiver or alteration; and,
- whenever appropriate, the subjects
will be provided with full disclosure
or additional pertinent information after
the research or experimentation project
is completed.
- Research Involving Archival Review, Statistical
Compilation or Record Review.
- Research which is limited to archival
review, statistical compilation or record
review may be carried out pursuant to Title
34, M.R.S.A., Section 1207(2). Such research
may be carried out without informed consent
provided that:
- said research is reviewed and approved
by a Research and Experimentation Review
Board;
- all data involved in said research
shall not be identifiable as to individual
recipients of services;
- the research plan shall be submitted
to, and approved by, the head of the mental
health facility or his or her designee.
- Research Involving Minors, Persons Unable
to Give Informed Consent, and Involuntary Recipients.
- No experimentation or research involving
more than minimal risks shall be conducted
with persons unable to give informed consent,
minors, or involuntary patients unless:
- the experimentation or research poses
a clearly expected benefit to the individual
recipient involved; and,
- the experimentation or research
has been reviewed and approved by the
Research and Experimentation Review Board.
- Notwithstanding the provisions of sections
A.XI.H.1. and A.XI.H.2, in the case of recipients
under the age of 18 and in the case of recipients
adjudicated incapacitated, consent must in all
instances be obtained from the recipient's
legally responsible parents, guardians or
custodians, and such consent must be reviewed
by the Rights Protection and Advocacy Services
of the state mental health system.
- In the case of minor recipients over
the age of 12, informed consent must also
be obtained from the prospective recipient
participant, except as described in sections
AXI.H.1. and A.XI.H.2. This provision does
not change the provision in section A.XI.H.3.b.
requiring the consent of the legally responsible
parents, guardians or custodians.
- Any use of drugs approved by the Food and
Drug Administration, when applied in an unlabeled
manner, shall receive prior approval from the Clinical
Director or equivalent.
I. Applicability
- Questions regarding the applicability of this
section to specific recipients or activities shall
be referred in writing to the Chairperson of the
Research & Experimentation Board who shall determine
applicability.
- Where disagreement continues to exist, questions
may be presented through the Grievance Procedure,
Section VI.
- In issues regarding professional standards,
referral of the question may be made to the appropriate
national professional standards committee whose
decision shall be final and binding.
|